The article compares Pfizer and Zoetis, focusing on their divergent strategies regarding branded medicines. While Pfizer is acquiring replacements for drugs losing exclusivity to drive growth, Zoetis is facing a price war where it must cut effective prices to retain its franchises. This strategic divergence has led to contrasting financial guidance: Pfizer raised its 2026 revenue midpoint by $500 million driven by underlying business growth, whereas Zoetis lowered its outlook expecting a 1% to 3% organic revenue decline. Zoetis is currently navigating significant headwinds in its Companion Animal segment, which saw a 6% organic revenue drop in the second quarter of 2026, with Key Dermatology falling 16%. To combat new entrants using discounting and rebates, Zoetis has invested in gross-to-net strategies and adjusted prices on key products like Cerenia. Despite these challenges, the company maintains superior profitability with a 37.6% operating margin compared to Pfizer's core 26.7%, though Pfizer recently recorded $4.3 billion in noncash intangible asset impairments. Valuation metrics show Zoetis trading at a significant discount relative to Pfizer on an unadjusted price-to-EBIT basis (9.2x vs 23.9x), although the gap narrows when accounting for Pfizer's impairment charges. Over the trailing three years, Zoetis has averaged 5.0% revenue growth against Pfizer's -5.2%, while Zoetis lost 50.8% of its stock value over the past twelve months compared to Pfizer's 21.1% gain. The analysis concludes that Zoetis represents a better business at a better price, provided investors can endure the ongoing price war dynamics.